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Summary 
Mig is a chemokine of the CXC  subfamily that was discovered by differential screening of a 
cDNA library prepared from lymphokine-activated macrophages. The mig gene is inducible in 
macrophages and in other cells in response to interferon (IFN)-% We have transfected Chinese 
hamster ovary (CHO) cells with cDNA encoding human Mig and we have derived CHO cell 
lines from which we have purified recombinant human Mig (rHuMig). rHuMig induced the 
transient  elevation of [Ca2+]i in human  tumor-infiltrating T  lymphocytes (TIL) and in  cul- 
tured, activated human peripheral blood-derived lymphocytes. No responses were seen in hu- 
man neutrophils, monocytes, or Epstein-Barr virus-transformed B  lymphoblastoid cell lines. 
rHuMig was chemotactic for TIL by a modified Boyden chamber assay but rHuMig was not 
chemotactic for neutrophils or monocytes. The CHO cell lines, IFN-~/-treated human periph- 
eral-blood monocytes, and IFN-~/-treated cells of the human monocytic cell line THP-1 all se- 
creted multiple and identical HuMig species as revealed by SDS-PAGE. Using the CHO-de- 
rived rHuMig, we have shown that the species' heterogeneity is due to proteolytic cleavage at 
basic  carboxy-terminal residues, and that the proteolysis occurs before and not after rHuMig 
secretion by the CHO  cells.  The major species of secreted rHuMig ranged from 78 to  103 
amino  acids  in length,  the latter corresponding to the full-length secreted protein predicted 
from the HuMig cDNA. Carboxy-terminal-truncated forms ofrHuMig were of  lower specific 
activity compared to full-length rHuMig in the calcium flux assay, and the truncated species 
did not block the activity of the full-length species.  It is likely that HuMig plays a role in T  cell 
trafficking and perhaps in other aspects of the physiology of activated T  cells. 
C 
hemokines are members of a family of small,  induc- 
ible, and secreted proteins. The chemokines are active 
as  chemotactic  factors  and  growth  regulators,  and  exert 
their effects through seven transmembrane-domain G-pro- 
tein-coupled receptors (1,  2).  With  the  exception of the 
recently described chemokinelike factor lymphotactin (3), 
the chemokines contain four invariant cysteine residues and 
can be divided into two subfamilies.  In the 0~ or CXC sub- 
family, whose genes are found in a cluster on human chro- 
mosome 4, a single amino acid separates  invariant cysteines 
1 and 2.  In the [3 or CC subfamily, whose genes are clus- 
tered on human chromosome 17, invariant cysteines 1 and 
Portions of this work were presented  in abstract form at the Clinical Re- 
search Meeting of the American Federation for Clinical Research, 29 
April-2 May 1994, Baltimore, MD, and at the Experimental  Biology  95 
meeting, 9-13 April 1995, Atlanta, GA. 
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2  are adjacent.  The CXC ,chemokines can be subdivided 
further based on the presence or absence of an NH2-termi- 
nal region sequence, ELR, that is important for binding to 
the  IL-8  receptors  on  the  surfaces  of neutrophils  (4,  5). 
ELR-containing  chemokines  such  as  IL-8  function  as 
chemotactic factors for neutrophils.  The CC  chemokines 
are chemoattractants for a variety of cells,  such as mono- 
cytes, lymphocytes, basophils, eosinophils, and neutrophils 
(6-9). The chemokines are likely key components in con- 
ferring specificity on a number of the steps necessary for the 
selective  trafficking of distinct  populations  of leukocytes 
and subpopulations oflymphocytes (10). 
The  activities  of the  chemokines  are  not  limited  to 
chemotaxis, and the chemokines can act on cells other than 
peripheral blood leukocytes. For example, the chemokines 
have been shown to have effects,  primarily inhibitory, on 
the proliferation of myeloid progenitor cells  (11,  12);  the 
CC chemokines are active in stimulating exocytosis in hu- 
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genic factor (14); and other CXC chemokines, platelet fac- 
tor 4  (15) and IP-10 (16), can inhibit angiogenesis. 
Differential screening of a  cDNA library from lympho- 
kine-activated macrophages  led to  the  identification of a 
CXC  chemokine,  Mig  (17).  The  mig  gene  is  induced  in 
mouse  and human  monocytes/macrophages specifically in 
response to IFN-'y (17,  18). Mig, like platelet factor 4,  IP- 
10,  stromal  cell-derived  factor  (SDF)I-10t  and  SDF-115 
(19), is a CXC  chemokine lacking the ELR. sequence. We 
describe here the purification of recombinant human  Mig 
(rHuMig)  from  rHuMig-overexpressing Chinese  hamster 
ovary  (CHO)  cells and  we  report  the  initial biochemical 
and functional characterization of the HuMig chemokine. 
Materials and Methods 
Expression of rHuMig in Escherichia coli.  The  HuMig  cDNA 
(18) was cleaved with NlalV and PstI to give a 664-bp fragment 
that encoded the predicted HuMig protein minus the signal pep- 
tide,  including  residues  23-125  of the  HuMig  open  reading 
frame.  After making the  PstI  end blunt  using T4  DNA poly- 
merase, BamHI linkers were added and the fragment was inserted 
into the BamHI site of the pET-3b vector (20) 3' to a promoter 
for the T7 ILNA polymerase. The resulting plasmid was predicted 
to give rise to  an  mRNA  encoding a  fusion protein with the 
NH2-terminal 11  amino acids of the T7 bacteriophage gene  10 
protein followed by three additional residues (1KDP) and followed 
in turn by HuMig residues 23-125,  consisting of the entire pre- 
dicted,  secreted  HuMig  protein  (18).  The  gene  10  protein/ 
HuMig fusion protein was produced in E. coli strain BL21  (DE3) 
as described by Studier et al. (20). 
Expression of rHuMig in ClIO Cells.  Using  PstI,  a  785-bp 
fragment containing the entire coding sequence of HuMig was 
excised from the pBluescript SK-phagemid (Stratagene, La Jolla, 
CA) that contained HuMig cDNA (18). The termini were made 
blunt using T4 DNA polymerase and XhoI linkers were added, 
and the fragment was inserted into the XhoI site of pMSXND 
(21),  3'  to  a  mouse  genomic  fragnlent  containing  the  metal- 
lothionein  I  promoter and  5'  to  elements from  the  SV40  ge- 
nome, including the small t antigen intron and the early region 
polyadenylylation sequence,  pMSXND  contains a mouse dihy- 
drofolate reductase cDNA 3' to the early promoter of SV40 and a 
neomycin resistance  gene  3'  to  a  thymidine kinase  promoter. 
CHO  cells were proline auxotrophs  (21)  and were  a  kind gift 
from  Se-Jin Lee, Johns  Hopkins  University. pMSXND  DNA, 
containing the HuMig cDNA fragment in either the sense or the 
antisense orientation with respect to the metallothionein I pro- 
moter, was made linear by digestion with PvuI and was used to 
transfect CHO  cells by the lipofectin method according to  the 
manufacturer's protocol (GIBCO/BILL, Life Technologies, Gaith- 
ersburg, MD). Cells were grown in 400 p~g/ml G418 (GIBCO/ 
BILL,  Life Technologies) to  eliminate nontransfected cells,  fol- 
lowed by growth without G418 but with 0.2 p~M methotrexate 
1Abbreviations used in this paper: CHO, Chinese hamster ovary; CM, car- 
boxymethyl; MCP, monocyte chemotactic protein; MIP, macrophage in- 
flammatory protein; PVDF, polyvinylidene difluoride; rHuMig, recombi- 
nant  human  Mig; SDF,  stromal cell-derived  factor; TIL,  tumor- 
infiltrating lymphocyte. 
(Sigma Chemical Co.,  St.  Louis, MO)  in MEM  supplemented 
with 11.5 p~g/ml proline and 10% dialyzed FCS (Sigma Chemical 
Co.). Methotrexate-resistant colonies were picked and analyzed 
for production of rHuMig by growing the cells in 100 nM cad- 
mium sulfate, and subjecting supernatants to SDS-PAGE (22) fol- 
lowed by immunoblotting as described below. Cell line CHO/ 
H9  was  derived from  cells  transfected  with  DNA  having  the 
HuMig cDNA in the sense  orientation. Cell line CHO/IL5 was 
derived from cells transfected with DNA containing the HuMig 
cDNA in the antisense orientation. The CHO cell lines were not 
single-cell cloned. 
For  collecting  supernatants  for  protein  purification,  the 
rHuMig  overexpressing  CHO  cells  were  cultured  in  MEM-(x 
(GIBCO/BILL, Life Technologies), supplemented with 10% dia- 
lyzed FCS, 2 mM glutamine, and 0.2  btM methotrexate. When 
the cells became confluent, the culture medium was removed and 
replaced with serum-free MEM-~x with 100 nM cadmium sulfate, 
After 12-24  h,  the medium was discarded and fresh serum-free 
medium with cadmium was added. The harvesting and refeeding 
were done each 24 h and continued for 7 d and the supematant 
from day 2 to day 7 was used as starting material for the purifica- 
tion of rHuMig. 
Production of HuMig Antisera.  The  gene  10  protein/HuMig 
fusion protein expressed in bacteria was used to raise rabbit anti- 
sera JH49  and JH50.  Bacterial lysates  containing the  gene  10/ 
HuMig fusion protein were separated by SDS-PAGE under re- 
ducing conditions. The fusion protein was visualized using 0.05% 
Coomassie  brilliant blue,  the  band  excised,  and  the  gel  lyo- 
philized and pulverized for injection. New Zealand White rabbits 
were injected subcutaneously with material containing 100-200 
p,g of protein initially in complete, and subsequently in incom- 
plete Freund's adjuvant, approximately once per month over 16 
mo with regular bleeds. 
Antisera  JH49 and JHS0 were used for immunoblotting. These 
antisera, raised against denatured rHuMig,  were not efficient in 
immunoprecipitating HuMig,  particularly the  low-kD  HuMig 
species (data not shown). 
To raise antisera 5092,  a rabbit was injected with 100 bLg of the 
rHuMig high-kD species that had been purified from the overex- 
pressing CHO/H9 cell line, and the rabbit was boosted with 60- 
100  p,g of the rHuMig high-kD species per month over 3 too. 
Antiserum  5092  was  used successfully  for  immunoprecipitating 
the various forms of HuMig as described below. 
IgG was purified from rabbit serum using protein A-activated 
Acti-Disk cartridges (FMC Bioproducts, Rockland, ME) accord- 
ing to the manufacturer's protocol. 
SDS-PA GE, Silver Staining, and Immunoblotting.  In  general, 
samples were analyzed under reducing conditions using Tricine- 
SDS-PAGE  and  a  10-20%  gradient  gel  (Jule  Biotechnologies 
Inc., New Haven, CT) according to the method of Schagger and 
Von Jagow  (23).  For the  determination of apparent molecular 
weights,  a  Tris-glycine-SDS, 15%  acrylamide gel was  used  ac- 
cording to Laemmli (22). For immunoblotting, the proteins were 
electrotransferred to  nitrocellulose membranes  (Schleicher  and 
Schuell Inc., Keene, NH) using a solution of 10 mM sodium bi- 
carbonate, 3 mM sodium carbonate, pH 9.9/methanol of 8:2, in 
a TransBlot apparatus  (Bio-iLad Laboratories, Hercules, CA)  at 
45 V for 7 h in the cold. The membranes were blocked with 50 
mM  Tris/HC1,  pH  7.5,  150  mM  NaC1,  0.1%  Tween-20,  and 
10% milk (1-2% fat) and all incubations and washes were done in 
the presence of the blocking solution. Blots were incubated with 
rabbit anti-HuMig serum JH50  at  a  1:1,000  dilution, washed, 
and incubated with horseradish peroxidase-conjugated goat anti- 
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Grove, PA) at a 1 : 5,000 dilution, washed again, and visualized by 
chemiluminescence using the  ECL  reagents  according  to  the 
manufacturer's protocol  (Amersham  Corp.,  Arlington Heights, 
IL). The markers  used  routinely for the immunoblots were the 
prestained  protein  molecular weight  standards  from  GIBCO/ 
BIKL, Life Technologies. The high-kD species of HuMig (see be- 
low)  reproducibly comigrated with both prestained lysozyme  as 
well as with lysozyme that had not been prestained.  For this rea- 
son, the position of the prestained lysozyme on the immunoblots 
is  designated  as  14.3  kD,  lysozyme's reported  molecular mass, 
without regard  to changes in the mobility of the marker due to 
prestaining. Silver staining of proteins was performed according 
to the method of Blum (24). The markers used for silver-stained 
gels and for  the  determinations of apparent molecular weights 
were the Mark 12 wide-range proteins standards from Novel Ex- 
perimental Technology (San Diego, CA). 
Analysis of HuMig  Production by THP-1  Cells and by Peripheral 
Blood Monocytes.  THP-1 cells, derived from a human histiocytic 
lymphoma, were obtained from the American Type Culture Col- 
lection,  Rockville,  MD.  Human  peripheral  blood  monocytes 
were collected  from normal donors by elutriation by the Depart- 
ment of Transfusion Medicine, Clinical Center, National Insti- 
tutes of Health. THP-1 cells and monocytes were cultured rou- 
tinely in 1KPMI 1640  with  10%  FCS.  For  analysis of HuMig 
production by the THP-1 cell line, cells were incubated at a den- 
sity of 106 cells/ml for 30 h without or with 2,000 U/ml IFN-~/. 
For analysis of HuMig production by peripheral blood mono- 
cytes,  cells were incubated at a density of 106 cells/m/for 48 h 
without or with 2,000  U/rnl IFN-7. Protease  inhibitors leupep- 
tin 2 p-g/ml,  EDTA 1 raM, PMSF 0.5 mM, aprotinin 2 p-g/ml, 
bestatin 10  p-g/ml,  calpain inhibitor 17  ~g/ml, E-64  1 p-g/m/, 
and pepstatin 0.7  p,g/m/  (Boehringer Mannheim Corp.,  India- 
napolis, IN) were added to the cell supernatants  before the sam- 
ples were concentrated for analysis. Anti-HuMig serum 5092 and 
protein  A-Sepharose  (pharmacia  LKB  Biotechnology,  Piscat- 
away,  NJ)  were used for iimnunoprecipitation. The precipitates 
were  analyzed  by  Tricine-SDS-PAGE and  immunoblotting as 
described above. 
Purification ofrHuMig Proteins.  (a) Purification ofbigh-kD pro- 
teins.  The  culture  supernatants  from  rHuMig-overexpressing 
CHO/H9 cells were collected as described  above and made 50 
mM Tris/HC1 pH 7.5 and 0.5 mM EDTA. 8-10 liters of super- 
natant were loaded on a carboxymethyl (CM)-cellulose column 
(MetaChem  Technologies Inc.,  Torrance,  CA)  mounted on a 
ConSep LC100 liquid chromatograph  (Millipore  Co.,  Milford, 
MA) and the bound proteins were eluted with a linear gradient of 
0.025-1 M  NaC1 in 50 mM Tris/HC1 pH 7.5,  0.5 mM EDTA. 
The  high-kD  rHuMig species  eluted as  a  single  asymmetrical 
peak at ,"~0.5 M NaC1. Fractions containing  rHuMig were identi- 
fied by immunoblotting  and peak fractions were pooled, concen- 
trated  using the  Centriprep-3  device  (Amicon  Inc.,  Beverly, 
MA), and subjected to reversed  phase HPLC on a 46 cm ￿  15 
cm  C18  column (Vydac,  Hesperia,  CA).  The  rHuMig species 
were  eluted using a  gradient of 15-40%  acetonitrile in 0.05% 
TFA over 60 min at a flow rate  of I  ml/min on a liquid chro- 
matograph (model 1050; Hewlett-Packard Co., Palo Alto, CA). 
The column eluate was monitored at 280 nm, 205 nm, and, for 
reference,  at  450  nm.  The  high-kD rHuMig species  eluted at 
,'-~44 rain. (b) Purification of low-kD species. The flow-through 
from the CM-cellulose column as described above was collected, 
concentrated 20-40-fold using a  spiral  wound CH2  apparatus 
(Amicon Inc., Beverly,  MA), and the concentrate was dialyzed 
against 25 mM Tris/HC1 pH 7.5,  0.5  mM EDTA, and 25 
NaC1.  The dialyzed  sample  was reapplied  to  the  CM-cellulose 
column and the bound proteins were eluted with a linear gradient 
of 0.025-1  M  NaC1  in 25  mM  Tris/HC1,  pH  7.5,  0.5  mM 
EDTA. The ability of the low-kD rHuMig to bind to the CM- 
cellulose column after dialysis was presumably due to the lower 
ionic strength of the dialysis buffer ('--~0.02) as compared with the 
ionic strength of the initial CHO cell supernatants  (~0.17). The 
low-kD rHuMig species eluted as a single asymmetrical  peak at 
~0.4  M  NaC1. Fractions  containing rHuMig low-kD  species 
were identified by immunoblotting,  pooled, and concentrated us- 
ing Centriprep-3 and Centricon-3 devices.  150-200-1xl samples 
were chromatographed on a 1 cm ￿  30 cm Superose 12 HR col- 
umn (pharmacia  LKB Biotechnology) equilibrated with 25 mM 
Tris/HC1, pH 7,5, 0.15 M NaC1 and 0.5 mM EDTA. The rHu- 
Mig-containing  fractions were pooled, concentrated, applied to a 
46 cm ￿  15 cm C18 column, and eluted using a 60-min linear 
gradient of 23-30% acetonitrile in 0.05% TFA at a flow rate of 1 
ml/min. The low-kD rHuMig species eluted between 32 and 43 
min. 
HPLC  fractions  with  purified rHuMig were  evaporated  to 
dryness  and the protein was resuspended in 10 mM Tris/HC1, 
pH 7.5, at ~0.6 g/ml and stored at -70~ 
rHuMig protein concentrations were determined by the bicin- 
choninic acid  method (25) according to  the supplier's  protocol 
(Pierce Chemical Co., R,  ockfield, IL) using BSA as the standard. 
Nile-Terminal Amino Acid Analysis.  The  purified  rHuMig 
species were subjected to Tricine-SDS-PAGE  and transferred to a 
polyvinylidene difluoride (PVDF)  membrane (Trans-Blot; Bio- 
Rad Laboratories).  The membrane was stained with Ponceau S 
and destained with 0.1% acetic acid. The protein bands were ex- 
cised and the membrane was washed exhaustively with deionized 
water.  The PVDF membrane was placed in the Blott  TM  reaction 
cartridge  of a protein sequencer (model 470A;  Applied Biosys- 
terns Inc., Foster City, CA) and subjected to automated Edman 
degradation using the manufacturer's recommended cycles for gas 
phase delivery of TFA. The resultant phenylthiohydantoin  amino 
acid fractions were manually interpreted using an on-line HPLC 
(model  120A;  Applied Biosystems  Inc.)  and  (CR4;  Shimadzu 
Corp.,  Tokyo, Japan)  integrator.  The  protein  sequencing was 
done by the Harvard Microbiochemistry Facility. 
Electrospray Ionization Mass Spectrometry.  For mass determina- 
tions, purified rHuMig species were prepared by dissolving dried 
HPLC fractions in 30 ~1 of methanol/water (1:1). Mass spectra 
were recorded on a triple  quadrupole mass spectrometer (TSQ- 
700;  Finnigan-MAT, San Jose,  CA)  equipped with an electro- 
spray ion source.  Fractions  were brought to a concentration of 
50% methanol/0.5% acetic acid and directly infused at a flow rate 
of 1 p-I/rain.  The electrospray  needle was operated at a voltage 
differential of -3 to -4 keV. Spectra were recorded by scanning 
the m/z range of 400-2,000 in 3 s and averaging  16-32 scans. 
The electrospray  ionization mass spectrometry was performed by 
the Harvard Microbiochemistry Facility. 
Tumor-infiltrating Lymphocytes (TIL).  The TIL were prepared 
from human melanomas as described  (26). The F9 and B10 lines 
of TIL were maintained routinely in RPMI 1640 with 10% FCS 
containing 500 U/ml IL-2 (Cetus  Oncology Corp., Emeryville, 
CA) or 100 U/ml IL-2, respectively.  The TIL were periodically 
stimulated with PHA plus irradiated allogeneic PBMC. For stim- 
ulation, buff  3  , coats collected from normal donors by the Depart- 
ment of Transfusion Medicine, Clinical Center, National Insti- 
tutes  of Health, were treated with 5,000 rad.  The PBMC were 
purified by Ficoll-Hypaque (Pharmacia LKB Biotechnology Inc.) 
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tine culture medium with  250  ng/ml PHA  (Murex,  Dartford, 
UK). The TIL were suspended at 2 X 106 cells/ml and equal vol- 
umes of the suspensions of PBMC and TIL were mixed and cul- 
tured in 24-well culture plates  (Costar  Corp., Cambridge, MA) 
with 1 ml/well. After 3-4 d, 1 ml routine culture medium with- 
out PHA was added to each well. After 2-3 additional d, the cells 
were transferred to flasks at a density of 106 cells/ml. 
Activation of PBL.  The  elutriated PBL  and monocytes were 
collected  from normal donors by the Department of Transfusion 
Medicine,  Clinical Center,  National Institutes  of Health.  The 
PBL were purified further by banding on Ficoll-Hypaque. The 
purified lymphocytes were washed with Dulbecco's PBS and re- 
suspended in RPMI 1640 supplemented with 10% FCS,  100 U/ 
ml penicillin, 100  p~g/ml of streptomycin, and 5  p~g/ml PHA. 
The elutriated syngeneic monocytes were treated with 5,000 rad, 
washed with Dulbecco's PBS, and resuspended  in the same me- 
dium used for the PBL.  Equal volumes of the lymphocyte sus- 
pension (2  ￿  106  cells/ml)  and the  monocyte suspension (106 
cells/ml)  were mixed and cultured in 96-well round-bottomed 
plates for 4 d (27). 
Measurements of Calcium Flux.  Calcium flux assays were done 
according to the method of Grynkiewicz (28). For calcium mea- 
surements,  recombinant IL-8 was obtained from Biosource  (Ca- 
marillo,  CA), and recombinant human MCP-1  and IP-10 were 
obtained from PeproTech  (R.ocky  Hill,  NJ).  Neutrophils were 
prepared as  described  (29). B lymphoblastoid cell lines  81EBV, 
LAZ 509,  and 414EBV  were the kind gift of Robert Siliciano, 
Johns Hopkins University, and the  cells were  grown in R.PMI 
1640 with 10% FCS. TIL and PBL and monocytes were obtained 
and cultured as described  above.  Cells were suspended at a den- 
sity of 2 ￿  106 cells/nil in HBSS containing 1.3 mlM CaC12, 10 
mM Hepes,  pH 7.3, and 1% FCS. The cells were loaded with 2 
IzM Fura-2, AM (Molecular Probes Inc., Eugene, OR) for 1 h at 
30~  with occasional shaking. Loaded cells were washed twice by 
centrifugation and resuspended at a concentration of 106 cells/ml. 
The cell suspension was brought to 37~  and immediately before 
each assay 106 cells were collected by centrifugation, resuspended 
in 2 ml HBSS/Hepes/FCS, and added to a cuvette in a tempera- 
ture-controlled (37~  holder with continuous stirring.  Calcium 
measurements were done using a ratio fluorescence  spectrometer 
(model  P,F-M2001;  Photon  Technology  International, South 
Brunswick, NJ).  Excitation was alternately  at  340  and 380  nm 
with emission measured at 510 rim. Using an integration time of 
0.5 s the ratios of the signals obtained at the two excitation wave- 
lengths were plotted as a function of time. 
Measurements of Chemotaxis.  Assays for  lymphocyte  chemo- 
taxis using the B10 TIL were done by a modified Boyden cham- 
ber procedure using an MBC 96 microtiter plate chamber, 5-1*m 
pore  size polyvinylpyrrolidone-free polycarbonate  membranes 
(Neuro Probe, Cabin John, MD), and customized 96-microwell 
viewplates  (Polyfiltronics Group Inc., R.ockland,  MA). The B10 
TIL were preincubated at  5  ￿  106 cells/ml in R.PMI/1% FCS 
containing 10 p,M calcein, AM (Molecular Probes Inc.), at 37~ 
for 1 h. Dye-loaded ceils were pelleted,  washed, and resuspended 
in RPMI/1% FCS at  10  v cells/ml. Samples of RPMI/1% FCS 
without or with rHuMig were prewarmed to 37~  and ~400 p~l 
was placed in each microwell, the microweUs forming the lower 
chambers. Each test sample was loaded into three adjacent micro- 
wells. After assembling the apparatus, 50 I.d of the cell suspension 
was added to each upper well and the apparatus was incubated at 
37~  in 5% CO  2 for 3 h. After  disassembling the apparatus and 
removing the filter, the microtiter plate was centrifuged at 400 g 
at 4~  for 3 n'fin and the medium was aspirated from the micro- 
wells. The cells were washed in HBSS with repeat centrifugation 
and the  cells were  resuspended  and lysed  in HBSS  with 0.5% 
SDS. Fluorescence was measured using a microtiter plate reader 
(Titertek Fluoroskan II; Flow Laboratories,  Lugano, Switzerland) 
with excitation at 485 and emission read at 538 nm. Serial dilu- 
tions of the cell suspension had been added in place of test sam- 
ples to one row ofmicrowells for establishing a standard curve re- 
lating  fluorescence  intensity  to  cell  number  and  values  of 
fluorescence  intensity were converted into numbers of cells mi- 
grating by reference  to the standard  curve. The relationship  be- 
tween cell number and fluorescence  intensity was linear over the 
range of the experimental values that were obtained. 
Assays for  chemotaxis  of neutrophils  and  monocytes  were 
done using a 48-well microchemotaxis chamber (Neuro Probe) 
as described  (30). Neutrophils and monocytes were obtained as 
described above. For testing neutrophils, cells were used at a con- 
centration of 106/ml. The filter was polycarbonate, polyvinylpyr- 
rolidone-free,  with  3-1~m pores  (Costar  Corp).  For  testing 
monocytes, cells were used at a concentration of 1.5  ￿  106/ml. 
The filter was polycarbonate, polyvinylpyrrolidone coated with 
5-1*m pores  (Poretics  Corp., Livermore, CA).  Filters were ana- 
lyzed by counting the cells in five high-power fields per well. 
Results 
Production  of a  CHO  Cell Line  Secreting rHuMig.  CHO 
cells  were  transfected  with  the  pMSXND  plasmid  into 
which  had  been  inserted  HuMig  cDNA  sequences,  and 
rHuMig-secreting cell lines were  derived by selection in 
methotrexate as  detailed in Materials and Methods.  CHO 
cells were  chosen as  a  source of recombinant protein be- 
cause  they  could  be  manipulated to  yield lines secreting 
quantities of rHuMig far in excess  of what  could be  ob- 
tained from a natural source (see below) and because con- 
ditioned medium could be harvested from CHO  cells cul- 
tured without added protein, thereby simplifying rHuMig 
purification. In addition, CHO cells as compared with bac- 
teria  or  cells  of lower  eukaryotes,  could  be  expected  to 
process HuMig similarly to human cells. 
Transfection of CHO  cells with pMSXND  containing 
HuMig cDNA sequences in the sense orientation with re- 
spect to the mouse metaUothionein I promoter yielded the 
CHO/H9  cell line. The  CHO/I<5  cell line was  derived 
from cells  transfected with pMSXND  containing HuMig 
cDNA sequences in the antisense orientation. The CHO/ 
R5 cell line served as a source of control conditioned me- 
dium lacking rHuMig. 
As  described in Materials  and Methods,  rabbit antisera 
JH49  and JH50  were  raised  against  HuMig  protein  se- 
quences expressed in E.  coli and rabbit antiserum 5092 was 
raised  against rHuMig high-kD  species purified from  the 
CHO/H9  cell line (see below). 
As shown in Fig.  1,  the  cell line CHO/H9  secreted  a 
collection ofanti-HuMig-reactive  polypeptides. As expected, 
no rHuMig protein was produced by the parent, nontrans- 
fected CHO  cells,  or by the methotrexate-resistant CHO/ 
R.5 ceils that had been transfected with pMSXND contain- 
ing HuMig cDNA sequences in the antisense orientation. 
1304  Human Mig Chemokine Figure  1.  Production  of  rHuMig 
protein by transfected CliO cells. Cul- 
ture supematant was prepared from the 
parent CHO cell hne, from the pool of 
G418-resistant CHO cells after transfec- 
tion with  the pMSXND/HuMig  plas- 
mid,  and from the methotrexate-resis- 
tant cell hnes CHO/H9 and CHO/K5, 
the former derived from cells transfected 
with the pMSXND plasmid containing 
the HuMig cDNA in the sense orienta- 
tion  and  the  latter with  the  HuMig 
cDNA in the antisense orientation. 24-h 
supematants were collected from flasks 
containing confluent CHO cells and 50 
~1 of  the conditioned medium (contain- 
ing ,'ol.5  ~g total protein) was loaded 
per lane and analyzed by Tricine-SDS- 
PAGE and immunoblotting using anti- 
HuMig  serum JH50.  The  positions of 
prestained  protein  molecular weight 
standards (GIBCO/BRL  Life Technol- 
ogies) are shown. 
The initial  pool of transfected,  G418-resistant  CHO  cells, 
while  expressing  detectable  levels  of HuMig-hybridizing 
P,  NA  (not  shown)  did  not  secrete  sufficient  amounts  of 
protein for detection by Western blot.  For estimating rela- 
tive molecular masses the  CHO/H9  supematant  was ana- 
lyzed  by  Tris-glycine  SDS-PAGE  using  a  15%  gel  (not 
shown)  that  revealed  predicted  molecular  masses  for  the 
rHuMig species of'~8-36 kD. 
While  the  rHuMig  species  running  at  the  14.3-kD 
marker  and  below  had  predicted  molecular  masses  in  the 
11,725-M~  range  as  predicted  for the  secreted  protein  on 
the  basis  of the  HuMig  cDNA sequence,  it  was puzzling 
that  the  CHO  cells  produced  a  reduced  and  denatured 
rHuMig species running as a discrete band between the 29- 
and 43-kD markers  (Fig.  1).  Moreover,  production of this 
species was not unique  to the  CHO/H9  cell line but was 
found  in  supernatants  from  12  other  transfected,  metho- 
trexate-resistant,  rHuMig-secreting  CHO  cell  lines  (data 
not  shown).  Northern  blot  analysis  of the  HuMig  P,  NA 
species produced by the CHO/H9  cells  revealed evidence 
for  alternative  splicing  (data  not  shown).  Northern  blot 
analysis using oligonucleotide probes  and PCR  analysis of 
cDNA did not suggest the presence in the CHO/H9  cells 
of any HuMig RNA species where the HuMig stop codon 
had been  deleted  (data not shown).  Nonetheless,  we  con- 
sidered  whether  there  might  be  a  minor  P,  NA  species 
where  splicing had in fact deleted  the  HuMig stop  codon 
and  fused Mig sequences  with  those  of the  SV40 large  T 
antigen  from  the  pMSXND  vector.  We  investigated  this 
possibility by probing a Western blot of supernatants of the 
rHuMig-producing  CHO  cells  with  mAb  KT3,  whose 
epitope  is  in  the  carboxy-terminal  residues  of the  SV40 
large T  antigen (31), and found that, in fact, the low mobil- 
ity species that was immunoreactive with anti-HuMig anti- 
bodies was likewise  recognized by antibody KT3,  while 
none of the 8-14.3-kD rHuMig species reacted with KT3 
and  no KT3-reactive  species  were present  in  supernatants 
from control  CHO  cells  (data  not shown).  This  HuMig/ 
large T  antigen fusion protein was not investigated further. 
Comparison  of HuMig  Secreted by  CHO  Cells, Human 
Peripheral  Blood Monocytes, and  THP-1  Monocytic Cells. 
To compare the  CHO-derived  rHuMig and HuMig pro- 
duced by human cells,  monocytes, purified from peripheral 
blood  by  elutriation,  and  cells  of the  THP-1  histiocytic 
lymphoma line,  were treated  with  IFN-y and the cell su- 
pematants were analyzed by immunoprecipitation followed 
by Western blot analysis. Supematant from CHO/H9  cells 
was  added  to  supernatant  from  control  peripheral  blood 
monocytes, or control THP-1  cells,  and the mixtures were 
analyzed  in  parallel  with  the  samples  from  the  IFN-~/- 
treated cells.  Fig. 2  shows that after treatment with IFN-% 
both peripheral blood monocytes and THP-1 cells secreted 
a collection of HuMig polypeptides whose mobilities were 
identical  to  those  of species  produced by the  CHO  cells. 
For this  analysis,  supernatants  from IFN-~/-treated periph- 
eral blood monocytes and THP-1  cells were concentrated 
40-fold before  SDS-PAGE.  In Fig.  2,  in light  of the  data 
presented below, we have divided the HuMig species into 
two groups, labeled high- and low-kD, and we will refer to 
these HuMig species as high- and low-kD in the remainder 
of the paper. 
Analysis  of the  Basis for  the  HuMig  Species of Differing 
Mobilities.  The production of HuMig polypeptides of dif- 
fering  mobilities  was  most  likely  due  to  posttranslational 
modification,  either augmentation of the mass of the poly- 
peptide by glycosylation, and/or proteolytic cleavage of the 
full-length protein. The predicted HuMig protein lacks the 
sequence  for N-linked  glycosylation, and in  other experi- 
ments  not  shown,  digestion  of rHuMig  with  peptide-N- 
glycosidase  F  or  with  O-glycanase  failed  to  demonstrate 
Figure  2.  HuMig  produced  by  IFN-~-stimulated  peripheral blood 
monocytes and THP-I cells, compared with rHuMig produced by CHO 
cells. Peripheral blood monocytes were cultured at a density of 106 cells/ 
ml for 48 h without or with 2,000 U/ml IFN-~/ (A). THP-1 cells were 
cultured at a density of 106 cells/n'd for 30 h without or with 2,000 U/ml 
IFN-3' (B). 40 ml of culture supematant from monocytes and 30 ml of 
culture supernatant froms THP-1 cells were collected. Before processing 
for analysis, conditioned medium from the rHuMig-producing cell line 
CHO/H9 was added to a sample taken from monocytes and from THP-1 
cells incubated without IFN-% 1 ml of CHO/H9-conditioned  medium 
was added to the monocyte sample, and 0.75 ml was added to the THP-1 
sample. After collection  of  the supernatants, protease inhibitors were added 
and the samples were concentrated, subjected to immunoprecipitation us- 
ing anti-HuMig serum 5092, and analyzed by Tricine-SDS-PAGE and 
irnmunoblotting. The positions of prestained markers are designated on 
the left. The high- and low-kD species of HuMig are indicated on the 
right (see text). 
1305  Liao et al. any N-linked  or O-linked  sugar.  Experiments  were  done 
to determine  whether proteolysis was responsible  for gen- 
erating  the  multiple  rHuMig  species  and  if so,  whether 
proteolytic  processing  occurred before  or  after  the  secre- 
tion of rHuMig from the cell. 
Supernatants  were  harvested  from  CHO/H9  cells  and 
incubated at 37~  and analysis of serial samples showed no 
change  in  the  pattern  of rHuMig immunoreactive  species 
over  8  h,  i.e.,  no  conversion  of high-  to  low-kD  forms 
(data not shown). Next, medium was harvested from CHO/ 
H9 cells that had been incubated with or without protease 
inhibitors  for various times from 1 to 24 h,  and the media 
from the  1-12-h time  points were  concentrated appropri- 
ately so as to normalize the rHuMig concentrations among 
the samples. Western blot analysis of rHuMig produced by 
CHO/H9  cells  incubated  without  protease  inhibitors,  as 
shown in Fig.  3, revealed that the pattern  of rHuMig spe- 
cies did not change significantly over time, i.e., there was no 
evidence of processing occurring after secretion of the pro- 
tein into  the  medium.  In the  presence  of protease  inhibi- 
tors, only the high-kD species accumulated, consistent with 
our  presumption  that  the  low-kD  species  were  derived 
from  the  high-kD  species  by proteolytic  processing.  The 
effect of the protease inhibitors is consistent with proteoly- 
sis occurring before secretion since it has been shown that 
these  agents  can  inhibit  intracellular  proteolysis  (32-34). 
The relationships  among the various rHuMig species were 
clarified further after the proteins' purifications. 
Purification ofrHuMig.  CHO/H9  cells  were  grown  in 
protein-free  medium  and  culture  supernatant  was  used  as 
the starting material for the purification of rHuMig. As de- 
scribed  in  Materials  and  Methods  CM-cellulose  chroma- 
tography separated rHuMig into high- and low-kD species. 
The high-kD rHuMig species was purified additionally by 
reversed phase chromatography. The low-kD rHuMig spe- 
cies were  purified  by repeat  application  to  CM-cellulose, 
followed by size-exclusion and reversed phase chromatog- 
raphy. 
Fig.  4  shows separation  by SDS-PAGE followed by sil- 
ver staining or immunoblotting of the CHO/H9  superna- 
Figure  3.  Effect  of protease inhibitors on the processing of rHuMig. 
Confluent CHO/H9 cells were grown in serum-free medium in the ab- 
sence of protease inhibitors or in the presence of the protease inhibitors 
aprotinin (0.3 ~M), leupeptin (50 ~M), and N-l-tosylamide-2-phenyl- 
ethylchloromethyl  ketone (TPCK) (25 ~M). Supematants were collected 
at the times indicated. The  1-, 3-, 6-, and 12-h supematants were con- 
centrated 24-, 8-, 4-, and 2-fold respectively. 50 ~1 of each sample was 
analyzed by Tricine-SDS-PAGE  followed  by immunoblotting using anti- 
HuMig serum JH50. The positions of prestained markers are designated 
on the left. The high- and low-kD species ofrHuMig are indicated. 
Figure 4.  High- and low-kD species ofrHuMig purified from CHO/ 
H9 cells. (Left) Crude supernatant from CHO/H9 cells, containing 5 ~g 
of total protein and samples of  purified high- and low-kD rHuMig species 
containing 1 and 2 ~g of  protein, respectively, were analyzed  by Tricine- 
SDS-PAGE and silver staining. The positions of protein standards (Novel 
Experimental Technology) are noted on the left. (Right) Using the same 
samples as used for the left panel, crude supernatant from CHO/H9 cells 
containing 3 p.g of total protein, and aliquots of purified high- and low- 
kD rHuMig species containing 5 ng of protein each were analyzed by 
Tticine-SDS-PAGE followed by immunoblotting using anti-HuMig se- 
rum JH50. 
tant and of the purified rHuMig species.  Minor bands run- 
ning above the 14.4-kD marker, such as those evident with 
silver  staining  in  Fig.  4,  were  seen  routinely  with  SDS- 
PAGE analysis of  large amounts of purified rHuMig. These 
minor  species  were  immunoreactive  (discernible  but  not 
seen  easily on the  exposure  of the immunoblot in  Fig.  4), 
and their mobilities varied along with the mobilities  of the 
major  rHuMig  species  (see  Fig.  5),  so  that  we  presumed 
that these species represented  aggregates of the major spe- 
cies, formed during the processing for SDS-PAGE. 
NH2-Terminal and Mass Determinations of rHuMig Species. 
Four fractions of HPLC-purified rHuMig, containing rHu- 
Mig polypeptides  of varying mobilities,  were  subjected  to 
SDS-PAGE and the proteins transferred  to a PVDF mem- 
brane.  NH2-terminal  analysis of the  rHuMig polypeptides 
revealed a single predominant  sequence irrespective  of the 
species' mobilities,  namely TPVVR, the HuMig NH2-ter- 
minal sequence  that had been predicted  (18)  based on the 
empirically derived rules for signal-peptide cleavage. 
Analysis of similar  HPLC fractions by electrospray  ion- 
ization  mass  spectrometry  revealed  species  with  masses 
ranging from 11,723 to 8,464.  The predicted COOH-ter- 
minal residues  of the major species are indicated  in Fig.  5. 
In general,  cleavage has left  a basic  COOH-terminal  resi- 
due  typical  of the  products  of many  serine  proteases.  In 
addition,  the mass analysis confirmed the absence of glyco- 
sylation. The differences in binding properties of the high- 
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Figure 5.  Keversed phase chromatography of high- and low-kD rHu- 
Mig species showing results of NH2-terminal analysis and showing the 
predicted COOH termini of selected fractions. The high- and low-kD 
species of rHuMig obtained fi:om 10 liters of conditioned medium from 
CHO/H9 cells, were subjected to reversed phase chromatography on a 
Vydak C18 column as described in Materials and Methods. 10 ~1 of each 
HPLC  fraction was analyzed by Tricine-SDS-PAGE followed by silver 
staining, as shown in the upper panel, rHuMig species  from high-kD frac- 
tion 46 and low-kD fractions, 34, 37, and 39 were transferred to a PVDF 
membrane and the NH2-termmal sequences were determined. Compara- 
ble fractions from another HPLC  separation were analyzed by electro- 
spray ionization mass spectrometry. The mass values were used for deter- 
mining the rHuMig species' COOH termini. The predicted amino acid 
sequence of the unprocessed HuMig protein is indicated below with the 
site of cleavage  of the signal peptide for rHuMig shown by the down-go- 
ing arrow. The predicted COOH-terminal residues of the major rHuMig 
species are designated by the up-going arrows, 
and  low-kD  species for  CM-cellulose as  described above 
are understandable,  given that the low-kD species are de- 
rived t~om the high-kD species by cleavage of  basic COOH- 
terminal residues. The mass analysis established that HuMig 
species show anomalously decreased mobility when analyzed 
by Tricine-SDS-PAGE or by Tris-glycine-SDS-PAGE (not 
shown)  with the  11,725-Mr species, for example, running 
at a mobility of~14  kD. The basis for this anomalous be- 
havior is unknown, but may relate to the highly basic char- 
acter of the HuMig protein, and has been seen with other 
chemokines (35). 
Demonstration that rHuMig Targets T  Cells.  The  recep- 
tot's  for  the  chemokine  family  of cytokines  are  7-trans- 
membrane-domain  proteins  and,  in  general,  binding  of 
chemokines  to  their  receptors  leads  to  a  transient  rise  in 
[Ca2+]i  (2).  As shown  in  Fig.  6  rHuMig  failed to  cause  a 
rise in [Ca2+]i in neutrophils, monocytes, lymphocytes that 
had been freshly isolated from blood, or EBV-transformed 
B  lymphoblastoid cells. Furthermore, 100 ng/ml ofhigh-kD 
rHuMig  failed to  block an  rlL-8-induced calcium flux in 
Time (s) 
Figure 6.  Failure ofhigh-kD rHuMig to induce calcium fluxes in neu- 
trophils, monocytes, PBL, or EBV-transformed B cells.  At the times indi- 
cated by the solid arrows, high-kD  rHuMig  was added to  106 Fura-2, 
AM-loaded cells in 2 ml HBSS/Hepes/FCS  to give a final concentration 
of rHuMig of 100 ng/rnl. At the times indicated by the open arrows, 10 
ng/ml rlL-8 was added to the neutrophils and 50 ng/ml ofrMCP-1 was 
added to the monocytes. The cells were obtained and the fluorescence 
measurements were done as described in Materials and Methods. No re- 
sponses to the purified high-kD rHuMig were seen for neutrophils from 
two donors in three experiments, for monocytes from two donors in two 
experiments, for freshly isolated PBL from two donors in two  experi- 
ments, and for EBV-transformed B lymphoblastoid cell lines from three 
donors in two experiments. 
neutrophils or an rMCP-l-induced  calcium flux in mono- 
cytes. 
To limit the heterogeneity of the lymphocyte population 
being studied and because of the possibility that the respon- 
siveness of lymphocytes to  rHuMig might  depend on the 
cells' state of activation, we evaluated the effect ofrHuMig 
using TIL that  had been  derived from  human  melanomas 
(see Materials and Methods) and using a CTL clone specific 
for gpl60 of HIV type I  (36). 
TIL  lines  F9  and  B10  (see  below)  showed  a  rise  in 
[Ca2+]i in response  to  the purified high-kD  rHuMig pro- 
tein.  The  gp160-specific  CD4 §  CTL  clone  F14.38  (36) 
also  responded to  rHuMig  (not  shown).  Initial character- 
ization of the F9 and B10 lines revealed that >97% of cells 
from  both  lines  stained  positive  for  CD3  and  CD4  by 
FACS  |  analysis (data not shown). These TIL lines could be 
maintained in  culture with  intermittent  restimulation  (see 
Materials and Methods),  and they were used in the studies 
shown below. 
Experiments were done to demonstrate that the calcium 
response in TIL was due to rHuMig and not due to a con- 
taminating protein present in amounts below the limits of 
detection  of our  analyses  by  physical  methods,  rHuMig 
peak fractions and adjacent fractions from the final reversed 
phase  chromatography purification of the high-kD  species 
were  tested  for  their  activities  on  the  F9  TIL  line.  As 
shown  in  Fig. 7,  the  peak of activity corresponded to  the 
rHuMtg protein peak. 
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Figure 7.  Reversed phase chromatography ofrHuMig high-kD species 
showing coelution ofrHuMig protein and the factor causing calcium flux 
in TIL.  160  p,g of high-kD CM-cellulose-purified rHuMig was loaded 
on a Vydak C 18 column, rHuMig was eluted using a gradient of increas- 
ing concentrations of acetonitrile and 1-ml fractions were collected. The 
HPLC chromatogram is shown as an inset. Fractions were assayed for the 
ability to cause a calcium flux in Fura-2, AM-loaded F9 T￿93  Appropriate 
dilutions were made of fraction 42 to be within a dose-responsive range 
for measuring factor activity, and other fractions were diluted identically. 
Protein determinations were done on each fraction. Both the peak ratio 
of fluorescence intensities and the protein concentration for each fraction 
are expressed as a percentage of the maximum values. 
Antisera JH49 and JH50, which had been raised against 
E.  coli-derived  rHuMig,  could neutralize the  activity of 
CHO/H9-derived rHuMig on TIL. Neutralization using 
IgG purified from one of the  rabbits  is shown in Fig.  8. 
Neutralization required preincubation of rHuMig with the 
anti-HuMig IgG. Neutralization was not due to any direct 
effect of the  IgG on the TIL, since  the lymphocytes re- 
sponded to rHuMig added alone subsequent to the addi- 
tion of the preincubated rHuMig-anti-rHuMig mixture. 
Determination  of the  Dose  Response of  TIL  to  High-kD 
rHuMig  and  to  rHuMig  with  a  Deleted  Carboxy  Terminus. 
Fig. 9 A demonstrates the dose response of the F9 TIL line 
to a preparation of the high-kD rHuMig consisting prima- 
rily of the  full-length,  103-amino  acid  species,  with  an 
ECs0 of "-~3 ng/ml. In Fig. 9 B is shown the dose response 
using rHuMig with carboxy-terminal deletions, equivalent 
to the material seen in fraction 39 in Fig. 5 where the ma- 
jor rHuMig species was 78  amino acids in length. While 
this rHuMig fraction does have some activity, it is <1/300 
the activity of the high-kD rHuMig. Fig.  9  B also shows 
that the carboxy terminal-deleted rHuMig, when added at 
1,000 ng/ml still did not produce a maximal rise in [Ca2+]i, 
and 1,000 ng/ml of the terminal-deleted species attenuated, 
but failed to block completely the response to 3 ng/ml of 
the high-kD rHuMig. The failure of the low-kD rHuMig 
species  to eliminate completely the response to the high- 
kD  species  does not suggest that the rHuMig species  are 
working through different receptors or signaling pathways, 
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Figure 8.  Neutralization of the factor stimulating a calcium flux in TIL 
using antibodies against rHuMig. 14 ng of high-kD rHuMig was preincu- 
bated for 3 h  at 4~  in 50 Ixl ofDulbecco's PBS alone, or with 50 p~g of 
IgG from a  nonimmunized rabbit,  or with 50  p~g of IgG purified from 
anti-HuMig rabbit serum JH49. As indicated by the solid arrows, prein- 
cubated  material was  added  to  a  cuvette  containing  106  Fura-2,  AM- 
loaded B10 TIL in 2 ml of HBSS/Hepes/FCS. The open arrow indicates 
the addition of 14 ng ofhigh-kD rHuMig that had not been preincubated 
with IgG. 
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Figure 9.  Calcium fluxes in TIL in response to varying concentrations 
of high- and low-kD rHuMig.  (A)  High-kD rHuMig was added to  106 
Fura-2, AM-loaded F9 TIL in 2 ml of HBSS/Hepes/FCS when indicated 
by the arrows  to  give the final concentrations of high-kD rHuMig  as 
noted on the right. After stimulation with 10 ng/ml rHuMig, a second, 
identical aliquot of rHuMig was added as indicated by the arrow at 360 
s. (B) Low-kD rHuMig was added as in A to Fura-2, AM-loaded F9 TIL 
when indicated by the open arrows to  give the final concentrations of 
low-kD rHuMig as noted on the right. After stimulation with 1,000 ng/ 
ml of low-kD  rHuMig,  the cells were  challenged with 3  ng/ml of the 
high-kD rHuMig as indicated by the solid arrow. 
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by the arrows chemokine or buffer alone was added to 106 Fura-2, AM- 
loaded B10 TIL in 2 ml of HBSS/Hepes/FCS.  riP-10 was added at 60 s 
at 200 ng/ml and at 210 s at 10 ng/trtl. High-kD rHuMig was added at 
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points that extended below the baseline  were omitted for the sake of  clarity. 
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since the response to the low-kD  species was submaximal 
(see Fig. 9 A) and would therefore not be expected to pre- 
vent a response to a subsequent challenge. 
Demonstration that TIL Also Respond to riP-10.  We  were 
interested in  determining whether  rHuMig  was  the  only 
chemokine capable of inducing a  calcium flux in TIL. As 
discussed below, Mig shares features with IP-10 and since 
riP-10 had been reported to be chemotactic for activated T 
cells (37), we tested the response of the TIL to riP-10.  As 
shown  in  Fig.  10,  riP-10,  like rHuMig,  caused  a  rise  in 
[Ca2+]i in the B10  TIL.  To test rHuMig/rlP-10  cross-de- 
sensitization,  concentrations  of rHuMig  and  riP-10  that 
produced  maximal  responses  were  chosen  for  the  initial. 
challenges  and  concentrations  close  to  the  ECs0'S  were 
chosen  for  the  second  challenges,  riP-10  at  200  ng/ml 
blocked the response to a subsequent challenge with 2 ng/ 
ml  rHuMig  and  rHuMig  at  10  ng/ml  eliminated the  re- 
sponse  to  a  subsequent  challenge  with  10  ng/ml  riP-10, 
demonstrating cross-desensitization by rHuMig and riP-10 
in the BI0 TIL. 
Demonstration that PBL Can Respond to rHuMig.  Because 
we were  able to  demonstrate a  rise in  [Ca2+]i in  TIL but 
not in freshly isolated PBL in response to rHuMig, we hy- 
pothesized that lymphocytes might need to be activated to 
respond to rHuMig.  PBL were obtained from normal do- 
nors by elutriation followed by Ficoll-Hypaque discontinu- 
ous  density  gradient  centrifugation  and  the  lymphocytes 
were  cultured for 4  d  with PHA and irradiated syngeneic 
monocytes. Calcium fluxes in response to various concen- 
trations of rHuMig are shown in Fig.  11. These data dem- 
onstrated  that  rHuMig-responsive  cells could be  detected 
in the PBL population after culture and activation in vitro. 
Lymphocytes were tested from a total of five donors and in 
four of the five the lymphocytes showed a rise in [Ca2+]i in 
response  to  rHuMig.  In  general,  the  activated  PBL  re- 
Figure 11.  rHuMig-induced calcium fluxes in PBL that had been cul- 
tured and activated in vitro. Human PBL, purified from a normal donor 
by elutriation followed by banding on Ficoll, were incubated for 4 d in 
the presence of PHA and irradiated syngeneic monocytes. After loading 
with  Fura-2,  AM,  106  lymphocytes in  2 ml HBSS/Hepes/FCS  were 
stimulated at the times indicated by the arrows with the concentrations of 
high-kD rHuMig as noted on the right. 
quired a higher concentration of rHuMig to detect a rise in 
[Ca2+]i as compared with the TIL. 
Demonstration  that rHuMig Is  Chemotactic  for TIL,  B10 
TIL  were  loaded  with  the  fluorescent  vital  dye  calcein, 
AM, and we determined the TIL migration across a poly- 
carbonate fdter in response to rHuMig. Data from a repre- 
sentative experiment are displayed in  Fig.  12.  When  5  ￿ 
105 cells were placed in the upper chamber with 25 ng/ml 
of the high-kD rHuMig in the lower chamber, N1.4  ￿  10  s 
cells migrated into the lower chamber over the background 
number  of cells that migrated in  the  absence of rHuMig. 
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Figure  12.  rHuMig-induced  chemotaxis in  TIE  Calcein AM-loaded 
B10 TIL were analyzed for their migration toward various concentrations 
ofhigh-kD  species ofrHuMig  using a modified Boyden chamber assay. 5 
￿  105 ceils were added to the upper chambers and the numbers of ceils 
migrating across the polycarbonate filter into the lower chamber are ex- 
pressed as the means  --+  SE  of triplicate samples from one representative 
experiment. 
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Figure  13.  Failure of high-kD rHuMig to induce chemotaxis in neu- 
trophils and monocytes. Assays were done using a 48-well microchemo- 
taxis  chamber  and  polycarbonate  filters  as  described  in  Materials  and 
Methods. Each concentration of rHuMig was tested in triplicate wells and 
for each of the wells the cells in five high-power fields were counted. The 
average number of cells per high-power field is plotted for each triplicate 
+  SE. Chemotactic responses ofneutrophils to rlL-8 at the concentration 
indicated and of monocytes to  rMCP-1  at  the concentration indicated 
served as positive controls. A duplicate series of assays gave results identi- 
cal to those shown here. Neutrophils and monocytes were each obtained 
from a single (but different) donor. 
The  decrease  in  cell migration  seen  at higher  concentra- 
tions ofrHuMig produces the "bell-shaped" dose-response 
curve characteristic for chemotactic factors. When rHuMig 
at a variety of concentrations was placed not in the lower 
chamber, but in the upper chamber together with the cells, 
there was no migration of  B10 cells into the lower chamber 
over background  levels  (data  not  shown),  demonstrating 
that rHuMig has true chemotactic activity for the B10 TIL. 
As  shown  in  Fig.  13,  using  a  standard  microchemotaxis 
chamber (see Materials and Methods) the rHuMig high-kD 
species,  when  tested  at  5-100  ng/ml,  failed  to  elicit  a 
chemotactic response in neutrophils or monocytes, consis- 
tent with the absence ofrHuMig-induced calcium fluxes in 
these cells. 
Discussion 
We have demonstrated that HuMig is secreted as a col- 
lection of polypeptides that differ in their COOH  termini 
as the result ofproteolytic processing. We have shown that 
rHuMig  targets  activated  T  cells,  causing  both  a  rise  in 
[Ca2+]i  and  chemotaxis,  and  that  rHuMig's  ability to  in- 
duce a signal is diminished by removal of COOH-terminal 
residues. 
Both  chemokines  and  nonchemokine  cytokines  have 
been demonstrated to cause T  cells to chemotax (reviewed 
in  38).  Studies  of the  actions of chemokines on lympho- 
cytes have concentrated primarily on the CC or 13 chemo- 
kines,  and  these  studies,  while  not  always in  agreement, 
have  reported  differential  chemotactic  effects for  macro- 
phage inflammatory protein (MIP)-lo~ versus MIP-I[3 (7- 
9)  and for regulated upon activation in normal T  cells  ex- 
pressed and secreted (RANTES)  (6)  on subpopulations of 
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lymphocytes.  It  has  been  demonstrated  recently  that 
monocyte chemotactic protein (MCP)-I  is able to induce 
transendothelial lymphocyte migration (39). 
While  the CXC  chemokines have been studied prima- 
rily  for  their  effects  on  neutrophils,  the  CXC  subfamily 
members IL-8 and IP-10 have been reported to be chemo- 
tactic for lymphocytes. Both IL-8 (40) and IP-10 (37) cause 
the migration of activated, but not of resting lymphocytes. 
The finding of lymphocyte chemotactic activity for IP-10 
is of particular relevance to our work because Mig and IP- 
10  show  a  number  of additional  similarities.  Along  with 
platelet factor 4  and SDF-1  (19),  IP-10 (37)  and Mig (18) 
lack the ELR motif shared among the other CXC chemo- 
kines, a motif that is crucial for binding and activating the 
IL-8 receptors (4, 5). Computer-assisted sequence compar- 
isons  reveal  that  HuMig  and  IP-10  are  somewhat  more 
closely  related  to  each  other  than  they  are  to  other 
chemokines (2).  In both the  mouse and the  human,  Mig 
artd IP-10 are inducible in macrophages by IFN-~/(17,  18, 
41, 42).  Moreover, our data demonstrate that like rHuMig, 
riP-10  can cause a  calcium flux in  TIL and  that  rHuMig 
and  riP-10  can each  desensitize  TIL to  subsequent  chal- 
lenge  with  the  other.  The  cross-desensitization  data  are 
consistent with rHuMig and riP-10 binding to identical re- 
ceptor(s). Cross-desensitization by two ligands does not es- 
tablish,  however,  that  their  receptor(s)  are  shared.  For 
example, the chemoattractants formylpeptide and CSa dem- 
onstrate  cross-desensitization  when  tested  on  neutrophils 
despite  their  binding  to  separate  hepta-helical  receptors 
(43)  and IL-8 can desensitize neutrophils to C5a (44).  De- 
spite the similarities, there is evidence that the activities of 
HuMig and IP-10 are not identical. In contrast to what has 
been reported for riP-10  (37),  we have not thus far found 
HuMig  to  act  on  monocytes.  And  in  assays  of  neo- 
vascularization in mice, riP-10 but not rHuMig was found 
to be inhibitory (16). 
Given that other CXC and CC chemokines that act on 
lymphocytes have been found to target also either mono- 
cytes or neutrophils,  HuMig's T  cell specificity is unusual. 
In  this  regard,  HuMig  resembles lymphotactin  (3),  a  re- 
cently described cytokine that is similar to the CC chemo- 
kines  but  that  lacks  two  of the  four  invariant  cysteines 
found in the CC and CXC subfamilies. 
While  the  response  to  chemokines  typically includes  a 
rise in  [Ca2+]i as the result of the activation of a 7-trans- 
membrane-domain G  protein-coupled receptor (2),  there 
is  a  paucity  of reports  of induction  of calcium  fluxes  in 
lymphocytes by  chemokines.  Lymphotactin  has  been  re- 
ported  to produce  a  calcium flux in  CD4+-depleted  thy- 
mocytes  (3).  And  LCF,  a  nonchemokine  factor  that  is 
chemotactic for CD4 + T  cells, monocytes, and eosinophils, 
has been shown to produce a rise in intracellular calcium in 
a  CD4 +  murine  T  cell hybridoma  (45).  As far as  we  are 
aware, our experiments with rHuMig are the first to show 
chemokine-induced  calcium  flux  in  TIL  or  in  cultured 
PBL. 
A  large body of work has  established a  central  role  for 
calcium in signal transduction after stimulation through the T  cell receptor, related both to activation of mature  cells 
(46,  47) and to apoptosis of immature cells (48,  49). A sig- 
nificant difference between HuMig-induced and CD3-in- 
duced calcium flux is that the former is transient while the 
latter is sustained (46,  50).  While the former is presumably 
mediated through trimeric G-protein(s), the latter is the re- 
sult of activation of receptor- and accessory-molecule-asso- 
ciated tyrosine kinases  (51).  There is nonetheless evidence 
that chemokine-dependent and CD3-dependent pathways 
can interact, since MIP-lo~ can inhibit the T  cell prolifera- 
tion that follows cross-linking of CD3 (52). 
Our  calcium  flux  experiments  have  demonstrated  the 
importance of COOH-terminal residues for the activity of 
rHuMig.  While,  like  Mig,  the  other  CXC  chemokines 
generally show  a  clustering  of basic  amino  acids  at  their 
COOH termini, the murine and human Mig proteins are 
unusual in the lengths of their highly basic COOH termini. 
The murine and human Migs are the longest of the CXC 
chemokines, and aligning the Mig sequences with those of 
the  other  CXC  chemokines  reveals  that  the  additional 
lengths  can be  attributed to  Mig's  carboxy terminus  (17, 
18). The methods of Chou-Fasman (53) and Robson-Gar- 
nier (54)  as  applied by the  MacVector software (Eastman 
Kodak, Rochester, NY) predict that the HuMig COOH- 
terminal region forms an oe-helix (data  not shown) consis- 
tent  with  the  structural  information  available  for  other 
chemokines (55). 
While NH2-terminal proteolytic processing is well rec- 
ognized among the chemokines as a modification of func- 
tional importance  (56),  there are few reports of COOH- 
terminal cleavage. For MGSA/gro, two  COOH-terminal 
residues are removed to produce the mature protein  (57) 
and  a  NAP-2  variant  has  been  identified lacking several 
COOH-terminal residues (58), but the extensive COOH- 
terminal  processing shown  for HuMig  has  not  been  de- 
scribed  for  other  chemokines.  We  have  shown  that  the 
CHO/H9 cell line and, after stimulation with IFN-% the 
THP-1 human monocytic line as well as human peripheral 
blood  monocytes  produce  the  same  processed  forms  of 
HuMig.  For the  CHO-derived rHuMig,  we  have  estab- 
lished that processing is due to proteolysis that occurs be- 
fore secretion of rHuMig into the medium. Based on our 
experiments using protease inhibitors,  serine proteases are 
likely responsible  for HuMig's  COOH-terminal  process- 
ing. 
Proteolytic processing at COOH-terminal domain basic 
residues  is  not  unique  to  HuMig  and other chemokines, 
but has been described for other secreted proteins, such as 
IFN-~/ (59) and tissue factor pathway inhibitor (60).  In the 
case of IFN-% as for HuMig, the proteolysis was demon- 
strated to occur in CHO cells before secretion (59). Little is 
known about the molecular details of the pathways for this 
sort of  processing. The patterns of HuMig cleavage and our 
protease inhibitor studies suggest that HuMig is not pro- 
cessed by  the  recently described  KEX2-related proteases 
that cleave hormones and growth factors at internal dibasic 
sites (61). 
Studies of the CXC chemokines platelet factor 4 and IL-8 
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have  shown  that  their  COOH-terminal  domains  are  of 
functional importance. COOH-terminal peptides of plate- 
let factor 4 have been shown to possess the immunoregula- 
tory activity (62) and the angiostatic activity (15) that have 
been ascribed to the full-length protein. For IL-8, deleting 
the COOH-terminal 0~ helical region led to significant de- 
creases in chemotactic function and in receptor binding (5), 
although  the  truncation  did  not  eliminate  either activity 
completely. In contrast, the murine MCP-1 contains a non- 
basic  COOH-terminal  domain of no demonstrated func- 
tional importance (63).  The mouse MCP-1  differs from its 
human homologue in having a 49-amino acid serine- and 
threonine-rich COOH-terminal  extension that is  heavily 
glycosylated (63).  Removal  of this  COOH-terminal  do- 
main has no effect on the chemotactic activity of the mu- 
line MCP-1 as assayed in vitro (63). 
Recent work, particularly with  IL-8 (64)  and MIPI-~ 
(9), has suggested that chemokine binding to both soluble 
and cell-surface/extracellular matrix-associated glycosami- 
noglycans  is  important  for chemokine  function.  Matrix- 
bound chemokine could provide a fixed gradient up which 
a cell could move. Both for IL-8 (64) and for platelet factor 
4 (65),  the COOH-terminal domains have been shown to 
be essential for this binding to glycosaminoglycans. In addi- 
tion, it has been proposed, based in part on data for C5a 
and  its  receptor,  that  the  basic  a-helical  domains  of the 
chemokines participate  in  the  initial  binding interactions 
with  acidic  residues  in  the  extracellular  domains  of the 
chemokine receptors (2). 
In  regard  to  a  nonchemokine  cytokine,  it  has  been 
shown recently that acidic fibroblast growth factor requires 
binding to heparin or cell-surface heparan sulfate to signal 
through  the  fibroblast  growth  factor  receptor  (66).  We 
have  shown  that  rHuMig  with  a  large  COOH-terminal 
deletion is not only much diminished in its activity in the 
calcium flux assay, but also  that the  truncated rHuMig is 
unable to block the activity of the full-length protein. This 
suggests  that decreased receptor binding may be the basis 
for diminished activity shown by the  truncated  rHuMig. 
Interactions with  cell-surface glycosaminoglycans such  as 
heparan sulfate might be important in the binding of Hu- 
Mig to its  receptor, and  these interactions would be  ex- 
pected to be affected by deletion of HuMig's COOH ter- 
minus. 
Since  COOH-terminal  cleavage  affects  the  activity of 
rHuMig,  at least  with  respect to  calcium flux in  T  cells, 
such processing could well have a regulatory role in vivo. 
While we have demonstrated that this processing is occur- 
ring before secretion for the CHO cells in culture, this does 
not eliminate the possibility that the susceptibility of Hu- 
Mig to an inactivating proteolytic cleavage is used in vivo 
to limit the duration of HuMig's activity after its secretion. 
In the case of IL-8, for example, it has been reported that 
inactivation can occur as the result ofprotease(s) present in 
serosal fluid (67). 
If, in vivo, proteolytic processing of HuMig occurs only 
before secretion, it raises the question as to what advantage 
would  be  conferred by  secreting  forms  of HuMig  with varying specific  activities.  Considering  the  likelihood  that 
the truncated forms of HuMig will bind less readily to gly- 
cosaminoglycans  in  extracellular  matrix  and  on  cell  sur- 
faces, as compared to the full-length HuMig,  it is possible 
that  in tissue,  as  the  distance  from the  HuMig-producing 
cell increases,  the immobilized forms of HuMig would be 
those more truncated  and less  active.  This would add an- 
other dimension to a chemotactic gradient that would now 
be formed not only by changes in ligand concentration, or 
density, but also by changes in the specific activities of the 
immobilized  ligands,  with  specific  activities  increasing  as 
the distance to the HuMig-producing cell diminishes. 
HuMig is induced in macrophages  (18) by the lympho- 
cyte product IFN-% and HuMig in turn targets activated T 
cells.  Experiments  in vivo have demonstrated lymphocyte 
recruitment  into skin at sites  of IFN-y injection  (68),  and 
our results make Mig a reasonable candidate for mediating 
these effects. Similarly, our demonstration that rHuMig can 
function  as  a  chemotactic  factor for TIL makes  HuMig a 
candidate  for  mediating  the  lymphocyte  chemotaxis  in- 
duced by supernatants  from explanted tumors (69)  and for 
mediating lymphocyte infiltration of tumors in vivo. 
Chemokines  have  been  suggested  to  play  key  roles  in 
regulating the adhesion and the migration of leukocytes as 
part  of the  multistep  process  of leukocyte  trafficking.  In 
particular,  chemokines  are  well-suited  to  provide  an  im- 
portant part of the specificity that is required for the differ- 
ing patterns  of recruitment  and recirculation seen for sub- 
populations of lymphocytes (10).  We will be interested  in 
determining what role Mig may have in the trafficking ofT 
lymphocyte subsets  and what effects Mig may have on as- 
pects of T  cell physiology generally. 
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